Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
REDW.ST Stock Summary
Top 10 Correlated ETFs
REDW.ST
In the News
REDW.ST Financial details
Company Rating
Neutral
Market Cap
3.28M
Income
-14.18M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-0.63
Forward P/E
-
PEG
-0.02
P/S
-
P/B
0.64
P/C
-
P/FCF
-0.63
Quick Ratio
8.32
Current Ratio
8.9
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.09
EPS next Y
-
EPS next Q
-
EPS this Y
4445.45%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
7307.41%
-
-
-
-
SMA20
-66.67%
SMA50
-75%
SMA100
-80%
Inst Own
-
Inst Trans
-
ROA
-95%
ROE
-126%
ROC
-0.96%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
2.65M
Shs Float
2.62M
-
-
-
-
Target Price
-
52W Range
0.03-4.9995
52W High
-
52W Low
-
RSI
32
Rel Volume
0.01
Avg Volume
509.63K
Volume
5.39K
Perf Week
-13.5%
Perf Month
-54.07%
Perf Quarter
-82.47%
Perf Half Y
-85.51%
-
-
-
-
Beta
0.487
-
-
Volatility
0.09%, 0.6%
Prev Close
0%
Price
1.185
Change
-5.2%
REDW.ST Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.35 | -0.3 | -0.35 | -0.22 | 0 | |
Operating cash flow per share | -0.39 | -0.23 | -0.35 | -0.26 | 0 | |
Free cash flow per share | -0.39 | -0.23 | -0.35 | -0.26 | 0 | |
Cash per share | 0.18 | 0.14 | 0.24 | 0.19 | 0 | |
Book value per share | 0.27 | 0.15 | 0.26 | 0.25 | 0 | |
Tangible book value per share | 0.14 | 0.02 | 0.16 | 0.15 | 0 | |
Share holders equity per share | 0.27 | 0.15 | 0.26 | 0.25 | 0 | |
Interest debt per share | 0.01 | 0 | 0.01 | 0 | 0 | |
Market cap | 45.09B | 33.08B | 14.84B | 1.23B | 0 | |
Enterprise value | 45.08B | 33.07B | 14.83B | 1.22B | -4.28M | |
P/E ratio | -2.82K | -2.28K | -700.15 | -94.15 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -2.57K | -3K | -691.51 | -78.11 | 0 | |
PFCF ratio | -2.57K | -3K | -691.51 | -76.73 | 0 | |
P/B Ratio | 3.71K | 4.67K | 933.92 | 80.17 | 0 | |
PTB ratio | 3.71K | 4.67K | 933.92 | 80.17 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -2.91K | -2.28K | -724.08 | -93.23 | 0.33 | |
EV to operating cash flow | -2.57K | -3K | -690.82 | -77.39 | 0.28 | |
EV to free cash flow | -2.57K | -3K | -690.82 | -76.03 | 0.22 | |
Earnings yield | 0 | 0 | 0 | -0.01 | 0 | |
Free cash flow yield | 0 | 0 | 0 | -0.01 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 0.53 | 0.45 | 0.72 | 0.86 | 0.33 | |
Current ratio | 3.72 | 1.19 | 2.86 | 4.1 | 5.39 | |
Interest coverage | -63.12 | -5.78K | -56.79 | -271.84K | -18.14 | |
Income quality | 1.13 | 0.76 | 1.05 | 1.2 | 1.09 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.41 | 0.46 | 0.28 | 0.34 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.02 | 0.25 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | -7.24 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.47 | 0.99 | 1.44 | 1.11 | 0 | |
ROIC | -1.3 | -2.05 | -1.31 | -0.85 | -1 | |
Return on tangible assets | -1.89 | -2.1 | -1.39 | -1.09 | -0.98 | |
Graham Net | 0.14 | 0.02 | 0.16 | 0.14 | 0 | |
Working capital | 6.17M | 1.1M | 9.91M | 9.04M | 3.92M | |
Tangible asset value | 6.21M | 1.14M | 9.96M | 9.08M | 13.58M | |
Net current asset value | 6.17M | 1.1M | 9.91M | 9.04M | 3.92M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 137.07K | 266.42K | 349.31K | 568.78K | 616.99K | |
Average payables | 571.52K | 837.9K | 1.51M | 1.99M | 1.09M | |
Average inventory | -137.07 | -265.92 | -348.81 | -349.04K | -348.82K | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 339.56 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 1.07 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.32 | -2.05 | -1.33 | -0.85 | -1.04 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -0.08 | -0.04 | -0.04 | -0.01 | 0 | |
Operating cash flow per share | -0.05 | -0.05 | -0.03 | -0.02 | 0 | |
Free cash flow per share | -0.05 | -0.05 | -0.06 | -0.02 | 0 | |
Cash per share | 0.19 | 0.05 | 0.01 | 0.03 | 0 | |
Book value per share | 0.25 | 0.12 | 0.08 | 0.06 | 0 | |
Tangible book value per share | 0.15 | 0.06 | 0.02 | 0.04 | 0 | |
Share holders equity per share | 0.25 | 0.12 | 0.08 | 0.06 | 0 | |
Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
Market cap | 1.23B | 2.05B | 3.7B | 2.34B | 0 | |
Enterprise value | 1.22B | 2.05B | 3.7B | 2.33B | -4.28M | |
P/E ratio | -62.66 | -128.76 | -231.88 | -163.04 | 0 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -398.79 | -413.03 | -1.1K | -501.43 | 0 | |
PFCF ratio | -398.79 | -413.03 | -634.64 | -501.43 | 0 | |
P/B Ratio | 80.17 | 167.42 | 448.02 | 142.73 | 0 | |
PTB ratio | 80.17 | 167.42 | 448.02 | 142.73 | 0 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | -247.91 | -530.34 | -956.94 | -858.47 | 1.68 | |
EV to operating cash flow | -395.13 | -412.07 | -1.1K | -499.63 | 1.69 | |
EV to free cash flow | -395.13 | -412.07 | -634.4 | -499.63 | 1.07 | |
Earnings yield | 0 | 0 | 0 | 0 | 0 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0 | 0 | 0 | 0 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | 2.29 | 1.23 | 0.36 | 3.1 | 1.68 | |
Current ratio | 4.1 | 3.25 | 0.87 | 8.9 | 5.39 | |
Interest coverage | -272.9K | 10.85K | -42.43K | -3.8 | 0 | |
Income quality | 0.63 | 1.25 | 0.84 | 1.3 | 0.96 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.34 | 0.45 | 0.61 | 0.36 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.74 | 0 | 0.58 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -20 | 0 | -8.46 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0.68 | 0.33 | 0.27 | 0.14 | 0 | |
ROIC | -0.32 | -0.33 | -0.48 | -0.17 | -0.2 | |
Return on tangible assets | -0.41 | -0.52 | -1.01 | -0.32 | -0.18 | |
Graham Net | 0.14 | 0.04 | 0 | 0.03 | 0 | |
Working capital | 9.04M | 3.62M | -242.05K | 7.99M | 3.92M | |
Tangible asset value | 9.08M | 6.03M | 2.04M | 10.14M | 13.58M | |
Net current asset value | 9.04M | 3.62M | -242.05K | 7.99M | 3.92M | |
Invested capital | 0 | 0 | 0 | 0 | 0 | |
Average receivables | 658.07K | 600.64K | 400.41K | 442.28K | 561.87K | |
Average payables | 1.04M | 1.32M | 966.01K | 718.6K | 496.87K | |
Average inventory | -658.07K | -349.07K | -399.91 | -148.58 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 712.34 | 689.57 | 353.29 | 264.08 | |
Days of inventory on hand | 0 | -0.36 | -0.22 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0.13 | 0.13 | 0.25 | 0.34 | |
Inventory turnover | 0 | -246.76 | -417.38 | 0 | 0 | |
ROE | -0.32 | -0.33 | -0.48 | -0.22 | -0.19 | |
Capex per share | 0 | 0 | -0.02 | 0 | 0 |
REDW.ST Frequently Asked Questions
What is Redwood Pharma AB stock symbol ?
Redwood Pharma AB is a SE stock and trading under the symbol REDW.ST
What is Redwood Pharma AB stock quote today ?
Redwood Pharma AB stock price is $1.185 today.
Is Redwood Pharma AB stock public?
Yes, Redwood Pharma AB is a publicly traded company.